Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, IBBL Team to Bring Sequencing-based Tests to Luxembourg Physicians

NEW YORK (GenomeWeb News) – OncoDNA today said that it will collaborate with the Integrated BioBank of Luxembourg to provide physicians in Luxembourg with access to next-generation sequencing-based testing for cancer.

Specifically, OncoDNA was chosen by IBBL as a preferred supplier of molecular diagnostics for lung cancer. The Belgium-based firm will provide its OncoDEEP Dx cancer panel, which includes 50 genes and runs on the Ion Torrent PGM, under the alliance.

"With this partnership, OncoDNA continues to fulfill its aim of providing medical innovations based on targeted sequencing or complete sequencing of tumour genomes, in order to assist medical doctors in their treatment choices and provide better monitoring with regard to tumour development in the patient," Pierre Lefesvre, Co-founder and CMO of Onco DNA said in a statement.

OncoDNA was launched late last year. It is a subsidiary of Bio.Be, an affiliated company of the Institute of Pathology and Genetics in Belgium.

OncoDNA CEO and Co-founder Jean-Pol Detiffe told Clinical Sequencing News last December that the firm was offering a 48-gene Ion AmpliSeq cancer panel on the Ion Torrent PGM, and it planned to run the Ion 400-gene comprehensive cancer panel and exome sequencing on the Proton at the beginning of 2013.

It subsequently inked a partnership with CollabRx to develop solutions combining the results of cancer mutation panels developed by OncoDNA with clinically actionable and "dynamically updated knowledge" from CollabRx through that firm's SaaS-based technology and content resources.